Literature DB >> 23185710

Association of a Serotonin Receptor 2A Gene Polymorphism with Visual Sustained Attention in Early-Onset Schizophrenia Patients and their Non-Psychotic Siblings.

Nora S Vyas1, Yohan Lee, Kwangmi Ahn, Andrew Ternouth, Daniel R Stahl, Ammar Al-Chalabi, John F Powell, Basant K Puri.   

Abstract

The serotonin receptor 2A gene polymorphism is associated with attentional processes in schizophrenia. However, the specificity of the underlying cognitive constructs affected within this domain requires further elucidation. We carried out the first investigation of whether the TC/CC genotype of the 5-HT2A T102C polymorphism confers impairments in early-onset schizophrenia (EOS; onset of psychotic symptoms before age 18) but not in healthy siblings, the putative mechanism being that serotonergic inhibitory modulation of prefrontal dopamine is impaired in the presence of the C allele which in turn is a genetic risk marker for schizophrenia. Fifty-three EOS outpatients and 46 of their non-psychotic siblings (no current Axis I diagnoses) were genotyped for 5-HT2A T102C polymorphism. The Positive and Negative Syndrome Scale (PANSS) was used to assess symptomatology severity. Diagnostic classification was based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Structured Clinical Interview. The Degraded-Stimulus Continuous Performance Test (DS-CPT) was used to measure sustained focused attention. As predicted, EOS probands produced fewer correct responses (hit rate) and demonstrated poorer perceptual sensitivity compared with the healthy siblings. The C allele at codon 102 was associated with fewer correct responses compared with the TT genotype. There was no significant relationship between the polymorphism and clinical parameters, as measured using the PANSS. Our findings suggest that the C allele may be related to sustained attentional impairments in EOS.

Entities:  

Keywords:  Schizophrenia; T102C; HTR2A; adolescence; attention; biological relatives; gene polymorphism

Year:  2012        PMID: 23185710      PMCID: PMC3501364     

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   6.745


  54 in total

1.  What insights can we gain from studying early-onset schizophrenia? The neurodevelopmental pathway and beyond.

Authors:  Nora S Vyas; Sanjiv Kumra; Basant K Puri
Journal:  Expert Rev Neurother       Date:  2010-08       Impact factor: 4.618

Review 2.  Age of onset of schizophrenia: perspectives from structural neuroimaging studies.

Authors:  Nitin Gogtay; Nora S Vyas; Renee Testa; Stephen J Wood; Christos Pantelis
Journal:  Schizophr Bull       Date:  2011-05       Impact factor: 9.306

3.  Sustained attention in children at risk for schizophrenia: findings with two visual continuous performance tests in a new sample.

Authors:  J Rutschmann; B Cornblatt; L Erlenmeyer-Kimling
Journal:  J Abnorm Child Psychol       Date:  1986-09

4.  Age at onset and causes of disease.

Authors:  B Childs; C R Scriver
Journal:  Perspect Biol Med       Date:  1986       Impact factor: 1.416

5.  Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia.

Authors:  Y Inayama; H Yoneda; T Sakai; T Ishida; Y Nonomura; Y Kono; R Takahata; J Koh; J Sakai; A Takai; Y Inada; H Asaba
Journal:  Am J Med Genet       Date:  1996-02-16

Review 6.  Neurodevelopmental model of schizophrenia: update 2012.

Authors:  J L Rapoport; J N Giedd; N Gogtay
Journal:  Mol Psychiatry       Date:  2012-04-10       Impact factor: 15.992

Review 7.  Can genetics inform the management of cognitive deficits in schizophrenia?

Authors:  Nora S Vyas; Syed A Shamsi; Anil K Malhotra; Katherine J Aitchison; Veena Kumari
Journal:  J Psychopharmacol       Date:  2012-02-10       Impact factor: 4.153

8.  Visual sustained attention: image degradation produces rapid sensitivity decrement over time.

Authors:  K H Nuechterlein; R Parasuraman; Q Jiang
Journal:  Science       Date:  1983-04-15       Impact factor: 47.728

9.  Attentional abilities and measures of schizotypy: their variation and covariation in schizophrenic patients, their siblings, and normal control subjects.

Authors:  P Franke; W Maier; J Hardt; C Hain; B A Cornblatt
Journal:  Psychiatry Res       Date:  1994-12       Impact factor: 3.222

10.  Analysis of the attention deficit in schizophrenia: a study of patients and their relatives in Ireland.

Authors:  A F Mirsky; S L Yardley; B P Jones; D Walsh; K S Kendler
Journal:  J Psychiatr Res       Date:  1995 Jan-Feb       Impact factor: 4.791

View more
  5 in total

1.  Emotion moderates the association between HTR2A (rs6313) genotype and antisaccade latency.

Authors:  Mark Mills; Olivia Wieda; Scott F Stoltenberg; Michael D Dodd
Journal:  Exp Brain Res       Date:  2016-05-09       Impact factor: 1.972

2.  Genetic Variants Within Molecular Targets of Antipsychotic Treatment: Effects on Treatment Response, Schizophrenia Risk, and Psychopathological Features.

Authors:  Marco Calabrò; Stefano Porcelli; Concetta Crisafulli; Sheng-Min Wang; Soo-Jung Lee; Changsu Han; Ashwin A Patkar; Prakash S Masand; Diego Albani; Ilaria Raimondi; Gianluigi Forloni; Sofia Bin; Carlotta Cristalli; Vilma Mantovani; Chi-Un Pae; Alessandro Serretti
Journal:  J Mol Neurosci       Date:  2017-11-21       Impact factor: 3.444

3.  T102C polymorphism of serotonin-2A receptor gene in Turkish schizophrenia patients: Association with cognitive impairment and soft neurological signs.

Authors:  Adnan Özçetin; Burç Çağrı Poyraz; Cana Aksoy Poyraz; Erol Bozhüyük; Nurullah Bolat; İbrahim Balcioğlu; Anıl Çağla Özkiliç; Zehra Seda Genç; Müjgan Cengiz
Journal:  Indian J Psychiatry       Date:  2014-10       Impact factor: 1.759

4.  mRNA Expression and DNA Methylation Analysis of Serotonin Receptor 2A (HTR2A) in the Human Schizophrenic Brain.

Authors:  Sern-Yih Cheah; Bruce R Lawford; Ross McD Young; Charles P Morris; Joanne Voisey
Journal:  Genes (Basel)       Date:  2017-01-04       Impact factor: 4.096

5.  Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.

Authors:  Ping Lin; Junyu Sun; Xiaoyan Lou; Dan Li; Yun Shi; Zhenhua Li; Peijun Ma; Ping Li; Shuzi Chen; Weifeng Jin; Shuai Liu; Qing Chen; Qiong Gao; Lili Zhu; Jie Xu; Mengyuan Zhu; Mengxia Wang; Kangyi Liang; Ling Zhao; Huabin Xu; Ke Dong; Qingtian Li; Xunjia Cheng; Jinghong Chen; Xiaokui Guo
Journal:  Gen Psychiatr       Date:  2022-02-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.